For the first time since discontinuing its late-stage Alzheimer’s program, Merck has found promise on the path forward in the memory-robbing disease.

Psychedelic medicine firm MindMed (Nasdaq: MNMD)has dosed the first patient in a Phase 2b dose-optimization trial of MM-120, a pharmaceutically optimized form of lysergic acid diethylamide (LSD).

PORT-2 is an activator of this population. It has direct impact against tumors in terms of upregulating PD-L1 expression, which we know is favorable because it can

A broad range of serious diseases involve chronic inflammation, which causes both pain and progressive damage. Xalud Therapeutics is developing a locally-delivered, non-viral gene therapy that is designed to harness the ability of interleukin-10 to regulate the immune system and restore homeostasis. The company’s lead indication is in osteoarthritis We spoke to Diem Nguyen, CEO of Xalud, about the role inteleukin-10 plays in regulating multiple pathways in the immune system, Xalud’s gene therapy, and the indications the company is pursuing.

In this episode, the editorial team spoke with the President and CEO of regenerative medicine biotech Sernova Corp Dr. Philip Toleikis to learn more about how the company is developing a ‘functional cure’ for diabetes.

SOTIO Biotech, a clinical stage immuno-oncology company owned by PPF Group is starting its phase 2 trial on patients with selected advanced/refractory solid tumors.

Brad Margus is co-founder and Executive Chairman of Cerevance, a drug discovery company advancing a robust pipeline of targeted treatments for patients with neurodegenerative diseases, including Parkinson’s disease and Alzheimer’s disease.

SOT101 is an interleukin (IL)-15 superagonist that had demonstrated preclinical efficacy in various tumor models. Specifically, the agent prolonged survival and improved tumor regression in in vivo models. The agent also demonstrated a favorable toxicity profile preclinically.